[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355922-105":59,"doc-detail-355922-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","dysregulated-hells-expression-alters-cellular-processes-and-serves-as-a-potential-prognostic-marker-in-acute-myeloid-leukemia","Dysregulated HELLS expression alters cellular processes and serves as a potential prognostic marker in acute myeloid leukemia","","Dysregulated helicase lymphoid-specific (HELLS) expression affects chromatin-dependent cellular behavior in acute myeloid leukemia. Using an in vitro myeloid differentiation model, HELLS deficiency promotes myeloid differentiation, apoptosis, cell-cycle arrest, and chromatin instability, including stronger differentiation and apoptosis with chemotherapy agents such as 5-azacytidine, cytarabine, and doxorubicin. Epigenetic changes include reduced H3K4me3 and increased H3K27me3, alongside altered enhancer marks and chromatin accessibility. Transcriptomic and ex vivo analyses link HELLS upregulation to adverse prognosis and poorer survival, while HELLSLow groups show improved remission and reduced leukemic marker burden (CD123 and TIM-3).",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dysregulated-hells-expression-alters-cellular-processes-and-serves-as-a-potential-prognostic-marker-in-acute-myeloid-leukemia/355922/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dysregulated-hells-expression-alters-cellular-processes-and-serves-as-a-potential-prognostic-marker-in-acute-myeloid-leukemia/355922.png","ImageObject",300,407,{"name":92,"@type":93},"Franzy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What cellular processes are influenced by HELLS dysregulation in acute myeloid leukemia?","Question",{"text":113,"@type":114},"HELLS dysregulation alters myeloid differentiation, apoptosis, cell-cycle progression, and chromatin stability, with HELLS deficiency promoting differentiation and apoptosis while increasing chromatin instability.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does HELLS deficiency modify the epigenetic landscape?",{"text":118,"@type":114},"HELLS loss reduces the active histone mark H3K4me3, increases the repressive promoter mark H3K27me3, elevates the enhancer-associated mark H3K27ac, and changes chromatin accessibility.",{"name":120,"@type":111,"acceptedAnswer":121},"Why is HELLS upregulation considered a prognostic marker?",{"text":122,"@type":114},"Transcriptomic analyses and AML patient grouping show that higher HELLS expression associates with ELN-2017-defined adverse prognosis and significantly poorer survival, while lower HELLS expression links to favorable prognosis and improved remission.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355922,1790193996,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336478945519,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Dysregulated HELLS expression alters cellular processes and serves as a potential prognostic marker in acute myeloid leukemia  \nReceived for publication, August 13, 2025, and in revised form, May 18, 2026 Published, Papers in Press, May 28, 2026 [https://doi.org/10.1016/j.jbc.2026.1](https://doi.org/10.1016/j.jbc.2026.1)13210  \nSwati Madhulika 1,2, T Sayamsmruti Panda 1, Priyanka Samal3, Sreelakshmi S. Kumar 1, Smrutishree Mohanty1,2,  \nMonalisa Ghosh 1,2, Sohini Chakraborty4, Asima Das5, Jyochnamayi Panda5, Subha Saha6,7,8,  \nMrutyunjaya Padhy 1, Tareni Prasad Mallick 1, Preeti Pranjya Mohapatra 1, and Punit Prasad 1, *  \nFrom the 1Epigenetics and Chromatin Biology Unit, Biotechnology Research and Innovation Council (BRIC) - Institute of Life Sciences, NALCO Square, Bhubaneswar, Odisha, India; 2Regional Centre for Biotechnology, Faridabad, Haryana, India; 3Department of Clinical Hematology and Stem Cell Transplant, IMS & SUM Hospital & Medical College, Bhubaneswar, Odisha, India; 4Department of Pathology, New York University Grossman School of Medicine, New York, New York, USA; 5Department of Obstetrics and Gynaecology, Kalinga Institute of Medical Sciences Hospital, Bhubaneswar, Odisha, India; 6Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts, USA; 7Harvard Medical School, Boston, Massachusetts, USA; 8Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA  \nReviewed by members of the JBC Editorial Board. Edited by Brian D. Strahl  \nSpatiotemporal gene expression is regulated by the SNF2 family of ATPases that remodel chromatin, among which helicase lymphoid-specific (HELLS) play an essential role in DNA-templated processes. Analysis from cancer databases revealed HELLS upregulation in several cancers, including acute myeloid leukemia (AML). Using an in vitro myeloid differentiation model, we found that HELLS deficiency promotes myeloid differentiation, apoptosis, cell-cycle arrest, and chromatin instability. Furthermore, HELLS deficiency enhanced myeloid differentiation and apoptosis in HL-60 cells when treated with chemotherapy drugs, including 5-azacytidine, cytarabine, and doxorubicin. Epigenetically, loss of HELLS reduced active histone mark (H3K4me3) and enhanced repressive promoter (H3K27me3), active enhancer (H3K27ac) marks, and chromatin accessibility. Transcriptomic analysis of BeatAML data and bioinformatics analysis revealed that HELLS upregulation is associated with adverse prognosis, as defined by the ELN-2017 classification, and significantly poorer survival. Classification of AML patients into HELLSHigh and HELLSLow gene-expression groups showed that lower HELLS expression was associated with a favorable prognosis and improved remission. HELLS upregulation was positively and negatively associated with leukemic stem/progenitor cell (LSPC) markers and myeloid lineage markers, respectively. Ex vivo validation in AML patient-derived LSPCs demonstrated that HELLS deficiency reduces leukemic marker burden (CD123 and TIM-3) and increases apoptosis. Overall, we show HELLS upregulation drives leukemogenesis with poor outcomes, highlighting its potential as a prognostic marker and therapeutic target in AML.  \n* For correspondence: Punit Prasad, [punit@ils.res.in](punit@ils.res.in).  \nHelicase, lymphoid-specific (HELLS), also known as LSH, SMARCA6, and PASG, is a SNF2 family of chromatin remodelers, which was first identified in murine thymus (1, 2). HELLS expression is predominantly observed in proliferating tissues such as the thymus, bone marrow, and testis, whereas it is absent in nonproliferative tissues of the brain, heart, liver, and kidney. This highlights its critical role in regulating cellular proliferation across diverse cell lineages (2, 3). HELLSis associated with diverse DNA template-dependent processes, including DNA repair, recombination, methylation, cell cycle, and stem cell proliferation (4–6). F","cbCaiae7e5ao8iRU","https://ap.wps.com/l/cbCaiae7e5ao8iRU","pdf",6510336,"English","# Background\n# Methods and cellular effects\n# Epigenetic and transcriptomic findings\n# Patient stratification and ex vivo validation\n# Conclusions and clinical implications","[{\"question\":\"What cellular processes are influenced by HELLS dysregulation in acute myeloid leukemia?\",\"answer\":\"HELLS dysregulation alters myeloid differentiation, apoptosis, cell-cycle progression, and chromatin stability, with HELLS deficiency promoting differentiation and apoptosis while increasing chromatin instability.\"},{\"question\":\"How does HELLS deficiency modify the epigenetic landscape?\",\"answer\":\"HELLS loss reduces the active histone mark H3K4me3, increases the repressive promoter mark H3K27me3, elevates the enhancer-associated mark H3K27ac, and changes chromatin accessibility.\"},{\"question\":\"Why is HELLS upregulation considered a prognostic marker?\",\"answer\":\"Transcriptomic analyses and AML patient grouping show that higher HELLS expression associates with ELN-2017-defined adverse prognosis and significantly poorer survival, while lower HELLS expression links to favorable prognosis and improved remission.\"}]","Dysregulated HELLS expression alters cellular processes and serves as a potential prognostic marker in acute myeloid leukemia | PDF",1790121765,48,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2dc2524107d970f58db91a07d9eba6ee.webp",983,1296,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4b4c4f75951794c6fa883c8136fd3d3.webp",982,1294,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41afd23d4d91b5b13f38a7e8480538cf.webp",981,1293,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94dc4f5ccce42c538e60afed88b6968e.webp",980,1292]